I. First, a dose of reality: Many people are asking the wrong question.
Every day online, people ask, "Which two weight-loss peptides work best together?" Let me tell you, this question itself is flawed.
The real answer isn't "which two," but "which two pathways." Peptides are just tools; the pathways are the battlefield. If you only focus on the names of the peptides and prescribe them, it's like going to war with two kitchen knives-it looks impressive, but you have no idea how to use them.
So let's change our approach: categorize all the effective weight-loss peptides according to the "pathways" they work on, and then tell you which two pathways work together to force your body into a "must-lose-weight" situation.
II. Four main pathways, each with its own function.
Pathway 1: GLP-1-The "Signal Tower for 'I'm full, stop eating'"
Representative candidates: Semaglutide, Liraglutide, Dulaglutide
This pathway is the most popular and the most mature. The principle is simple and straightforward: it mimics the hormones secreted in your gut after a meal, tricking the brain into thinking you're "full," while simultaneously slowing gastric emptying, allowing insulin to be released on demand, and preventing glucagon from interfering.
Semaglutide alone resulted in an average insulin drop of 15.8% over 68 weeks. This is already considered a "miracle drug."
However, the problem is: GLP-1 only manages the portion "ingested," not the portion "burned." When you eat less, your body also slows down its metabolism, entering a "power-saving mode." This is why many people using GLP-1 experience a rapid drop in insulin levels in the first three months, followed by a slower decline, eventually hitting a plateau that refuses to go down.
Pathway Two: GIP – The "Insulin, Time to Get to Work" Supervisor
Representative: Tirzepatide (actually a dual target of GLP-1 and GIP)
GIP is an interesting hormone. It is also an incretin, but its function differs from GLP-1-GLP-1 controls "stop eating," while GIP controls "what to do after eating." It can enhance insulin secretion efficiency, improve fat metabolism, and may even have a slight effect of "making fat easier to burn."
Telboride binds GLP-1 and GIP to a single molecule, achieving a 22.4% weight loss at the highest dose over 72 weeks. This is nearly 7 percentage points more than using smegglutide alone.
However, GIP alone has a very weak weight loss effect. Its value lies in its ability to compensate for GLP-1's shortcomings in metabolic efficiency when used in conjunction with it.
Pathway 3: Glucagon (GCG) – The "Fat Depot Burner"
Representative: Retatrutide (GLP-1 + GIP + GCG triple target)
Glucagon is traditionally considered a "blood sugar booster," but new research has found that it has a completely different role in weight loss – increasing energy expenditure, promoting fat breakdown, and boosting basal metabolic rate.
Simply put: GLP-1 makes you eat less, GCG makes you burn more. One controls intake, the other controls output.
Retaglutide activates all three GLP-1, GIP, and GCG receptors. At the highest dose over 48 weeks, the average weight loss was 24.2%, and the curve hasn't peaked yet-meaning further weight loss is possible with continued use. The TRIUMPH-4 phase 3 trial in late 2025 was even more dramatic, with an average weight loss of 28.7% over 68 weeks, and some participants losing 71 pounds (approximately 32 kg).
What does this mean? This is approaching the effect of gastric bypass surgery (which averages 25-35% weight loss), but without the need for surgery.
Pathway Four: Amylin-The Master of Psychological Warfare for "Feeling Nauseous at the Sight of Food"
Representative Players: Cagrilintide, Pramlintide
Amylin is another hormone secreted by pancreatic β-cells, released along with insulin. Its effect is very "psychological"-it acts directly on the Area Postrema in the brainstem (near the vomiting center), causing a physiological aversion to food; it's not "not hungry," but "feeling disgusted at the sight of food."
It also slows gastric emptying, somewhat overlapping with GLP-1, but their sites of action are completely different.
Cagglitazone alone has a similar weight-loss effect to liraglutide. But its true power lies in its synergy with GLP-1.
III. The truly "killer" combinations are only two.
Having discussed the four pathways, now we can answer that question.
Combination 1: GLP-1 + Amylin – "Appetite Buster"
Representative: Canagglitazone + CagriSema
The logic of this combination is brilliant.
GLP-1 controls "physiological satiety"-when the stomach is full, hormonal signals are transmitted to the brain, telling you not to eat. Amylin controls "psychological aversion"-the brain directly loses interest in food; seeing fried chicken is no different from seeing a rock.
One works from the body, the other from the brain. With both pathways blocked simultaneously, you simply can't find a reason to eat.
A 2025 study published in the *New England Journal of Medicine* on the REDEFINE 2 phase III trial involved 1206 obese patients with type 2 diabetes. CagriSema (2.4mg + 2.4mg) resulted in an average weight loss of 13.7% over 68 weeks, compared to only 3.4% with placebo. More importantly, 73.5% of participants saw their HbA1c drop below 6.5%-meaning many went directly from diabetes back to normal.
Another meta-analysis is even more direct: CagriSema resulted in an additional 9% weight loss compared to semaglutide alone. Converted to absolute weight, this equates to an extra 9 kg lost over 20-32 weeks.
Another clinical case is even more interesting: three patients with type 1 diabetes (who already required insulin) simultaneously used semaglutide and pramlintide, resulting in a 16-23% weight loss over 10 months, while also reducing their insulin dosage. This demonstrates that the synergistic effect of amylin and GLP-1 is independent of whether or not a patient already has diabetes.
Who is this combination suitable for?
People with extremely strong appetites and severe emotional eating habits; people who respond poorly to GLP-1 alone and are stuck in a plateau; people with diabetes and obesity who need to control blood sugar and lose weight simultaneously.
Combination Two: GLP-1 + GIP + Glucagon – The "Metabolic Nuclear Warhead"
Representative Solution: Retatrutide (Three Targets in One)
This is no longer a "combination of two peptides," but a single molecule that simultaneously activates three receptors. Logically, it's like twisting three of the strongest pathways into one.
Let's break down what happens when these three pathways work together:
GLP-1: Eat less (reduce intake)
GIP: Optimize metabolism (improve processing efficiency)
GCG: Burn more (increase energy expenditure) Intake is reduced, output is increased, and intermediate processing efficiency is improved. Your body is forced into a "deficit" situation; without burning fat, there's no energy, no exceptions.
How solid is the data?
At 48 weeks, with a 12mg dose, the average weight loss was 24.2%. At 68 weeks (TRIUMPH-4), with a 12mg dose, the average weight loss was 28.7%. In the highest dose group, 100% of participants lost at least 5%, 93% lost at least 10%, 83% lost at least 15%, and a quarter lost more than 30%. In the 40-week diabetes trial, the 12mg group lost an average of 36.6 pounds (approximately 16.6 kg), and A1C decreased by 2.0%. Even more alarming is that the weight loss curve hasn't plateaued. At 48 weeks, weight continued to decrease. This means that if treatment continues until 72 or 96 weeks, the numbers could be even more dramatic.
An interesting detail is that in the TRIUMPH-4 trial, 14.1% (9mg group) and 12% (12mg group) experienced complete disappearance of knee pain. This wasn't due to painkillers, but because of weight loss, reduced joint stress, and decreased inflammation. This is the true "root cause treatment."
Who is this combination suitable for? For individuals who are extremely obese (BMI > 35), for whom single-drug therapy is ineffective; individuals with a complete metabolic syndrome breakdown-including high blood sugar, high cholesterol, high blood pressure, and fatty liver; individuals whose joints are already damaged due to weight and require "weight reduction" to preserve their knees; and individuals with strict requirements for weight loss speed (e.g., pre-operative weight loss, occupational needs).
IV. Why are other combinations not "game-changers"?
GLP-1 + GLP-1 (e.g., liraglutide + smegglutide)
I've written about this before. The logic is "fast start + long duration," but essentially it's an additive effect on the same pathway, not a complementary effect on different pathways. Receptor occupancy may reach saturation, leading to diminishing marginal returns. Clinical data is also lacking; it's in a state of "theoretically feasible, but no one has conducted large-scale trials in practice."
Simply GLP-1 + GLP-1 (Telborpeptide)
Telborpeptide is indeed stronger than GLP-1 alone, but the synergistic effect of GLP-1 is limited. It's more like a "strengthened version of GLP-1" rather than "opening up a new battlefield." The maximum weight loss of 22.4% has already been surpassed by Retaglutide's 28.7%.
Amylin alone... Canagliflozin alone is similar to liraglutide, but not as effective as smegglutide. Its value must be amplified in combination with GLP-1.
V. Side effects: The greater the potency, the higher the cost.
This is unavoidable.
CagriSema (GLP-1 + Amylin): Gastrointestinal reactions 72.5% (nausea, vomiting, diarrhea), but most were mild to moderate and transient. Slightly higher gastrointestinal reactions than semaglutide alone, but no increase in serious adverse events.
Ritaglutide (triple-target): Nausea 26.5%, diarrhea 22.8%, vomiting 17.6% (12mg group). Heart rate temporarily increases (both GLP-1 and GCG have positive inotropic effects), but decreases after 24 weeks. A unique side effect: dysesthesia (skin tingling or burning sensation), 4.5% in the 4mg group and 4.4% in the 12mg group, mostly mild and self-limiting. High discontinuation rate: 12% in the 9mg group and 18% in the 12mg group, mainly due to gastrointestinal intolerance.
Key conclusion: The more potent the combination, the greater the stress on the body to adapt. Not everyone can tolerate the highest dose. Stepwise dose increases, starting from a low dose, and dietary adjustments are the only ways to improve tolerance.
VI. My Personal Opinions (This section is based on experience, not data) Having worked in this field for so many years, I've seen countless people struggle with weight loss. Let me share some honest thoughts.
First, there is no "best combination," only the "most suitable combination for you."
If you are an emotional eater-binge-eating when stressed, ordering takeout when bored, or ordering food from videos you see late at night-then CagriSema (GLP-1 + amylin) might be more suitable for you. Because it cuts off your "interest" in food at its root; it's not about "resisting," it's about "genuinely not wanting" it.
If your metabolism is completely disrupted-severe insulin resistance, fatty liver, snoring, shortness of breath after walking a few steps-then Retaglutide's three-target approach might be more effective. Because it simultaneously addresses intake, metabolism, and expenditure, systematically rebuilding the system.
Second, don't mythologize any combination.
Retaglutide's 28.7% weight loss is an average; this means some people lose 40%, while others only lose 10%. Genetics, basal metabolism, gut microbiota, sleep, stress-these are variables that medication cannot control.
Third, medication is an accelerator, not an engine.
Your own diet, exercise, sleep, and stress management are the engine. Medication simply makes the engine run faster. If the engine is faulty, the accelerator will only make you crash faster.
I've seen too many people who, after starting medication, think, "The medication will cover everything," and continue drinking milk tea, eating late-night snacks, and staying up late. Three months later, when the dosage is increased, the effect is actually not as good as at the beginning. Why? Because the body has adapted, the metabolism has compensated, and the medication is waging a tug-of-war with your bad habits.
Fourth, rebound weight gain after stopping medication is more difficult than weight loss itself.
All GLP-1 drugs result in an average rebound of two-thirds within one year after stopping. This is not a problem with the medication; it's your body "finding balance." If you don't establish new eating and exercise habits during medication use, stopping medication will be a disaster.
VII. Summary in One Sentence
If you absolutely had to choose the "strongest combination":
Short-term burst of power + appetite control: Canagliflozin + Smegglutinin (CagriSema)
Long-term thoroughness + metabolic reconstruction: Retatrutide (three-target)
But remember-no combination can make you lose weight effortlessly. Medication opens a door; whether you can walk through it, and how far you go, depends on yourself.